Bristol Myers Squibb has completed the previously announced sale of its manufacturing facility in Couvet, Switzerland, to WuXi STA, a subsidiary of WuXi AppTec.

The divestiture is part of Bristol Myers Squibb’s ongoing progression of its manufacturing network to support its product portfolio. Switzerland remains an important strategic location for the company, and BMS expects to maintain a strong presence in the country.

The Couvet site is located in the canton of Neuchâtel, Switzerland. The site is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms.

WuXi STA is a pharmaceutical development and manufacturing company serving the life sciences industry. As a CDMO, WuXi STA offers services for integrated chemical, manufacturing and control (CMC) from preclinical to commercial uses. The acquisition significantly enhances WuXi STA’s drug product capacity in Europe and enhances capabilities by adding capacity to support its global customers. The Couvet site is the first facility in Europe for WuXi STA.